NASDAQ:GDRX GoodRx (GDRX) Stock Price, News & Analysis → Gold Set to EXPLODE! (From Gold Safe Exchange) (Ad) Free GDRX Stock Alerts $7.53 +0.06 (+0.80%) (As of 05/7/2024 ET) Add Compare Share Share Today's Range$7.31▼$7.6950-Day Range$6.47▼$8.3552-Week Range$4.14▼$9.37Volume1.72 million shsAverage Volume1.45 million shsMarket Capitalization$2.97 billionP/E RatioN/ADividend YieldN/APrice Target$8.78 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get GoodRx alerts: Email Address GoodRx MarketRank™ Stock AnalysisAnalyst RatingHold2.47 Rating ScoreUpside/Downside16.6% Upside$8.78 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment0.05Based on 14 Articles This WeekInsider TradingN/AProj. Earnings Growth34.78%From $0.23 to $0.31 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.57 out of 5 starsMedical Sector423rd out of 903 stocksData Processing & Preparation Industry27th out of 54 stocks 3.2 Analyst's Opinion Consensus RatingGoodRx has received a consensus rating of Hold. The company's average rating score is 2.47, and is based on 10 buy ratings, 8 hold ratings, and 1 sell rating.Amount of Analyst CoverageGoodRx has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about GoodRx's stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for GDRX. Previous Next 0.0 Dividend Strength Dividend YieldGoodRx does not currently pay a dividend.Dividend GrowthGoodRx does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GDRX. Previous Next 2.2 News and Social Media Coverage News SentimentGoodRx has a news sentiment score of 0.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.38 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for GoodRx this week, compared to 4 articles on an average week.Search InterestOnly 7 people have searched for GDRX on MarketBeat in the last 30 days. This is a decrease of -36% compared to the previous 30 days.MarketBeat Follows6 people have added GoodRx to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, GoodRx insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.37% of the stock of GoodRx is held by insiders.Percentage Held by Institutions63.77% of the stock of GoodRx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about GoodRx's insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for GoodRx are expected to grow by 34.78% in the coming year, from $0.23 to $0.31 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of GoodRx is -376.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of GoodRx is -376.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioGoodRx has a PEG Ratio of 3.89. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioGoodRx has a P/B Ratio of 3.90. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about GoodRx's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Smallcaps DailyThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySee how with its ongoing expansion and development of its diverse and promising product pipeline, this small-cap NYSE company is positioned to be a dominant and innovative leader in the nanomedicine and antiviral therapy space.Click to read About GoodRx Stock (NASDAQ:GDRX)GoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices. It also offers other healthcare products and services, including subscriptions, and pharma manufacturer solutions, as well as telehealth services through the GoodRx Care platform. It serves pharmacy benefit managers who manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was founded in 2011 and is headquartered in Santa Monica, California.Read More GDRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GDRX Stock News HeadlinesApril 22, 2024 | marketbeat.comWegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?The GLP-1 weight loss trend continues to flourish, and the ante keeps rising. The reigning champions in the battle of the bulge are Novo Nordisk A/V NYSE: NVO with its Semaglutide medications Ozempic and Wegovy, and Eli Lilly & Co. NYSE: LLY with its Tirzepatide medications Mounjaro and Zepbound.April 22, 2024 | marketbeat.comWegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs? (GDRX)The GLP-1 weight loss trend continues to flourish, and the ante keeps rising; see how the winner between Wegovy and Zepbound can help your portfolioMay 8, 2024 | Priority Gold (Ad)Biden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...May 7, 2024 | stockhouse.comGDRX Stockholders with Significant Losses Should Contact Robbins LLP for Information About the GoodRx Holdings, Inc. Securities Class ActionMay 7, 2024 | markets.businessinsider.comSHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of GoodRxMay 7, 2024 | prnewswire.comShareholders that lost money on GoodRx Holdings, Inc.(GDRX) Urged to Join Class Action - Contact The Gross Law Firm to Learn MoreMay 6, 2024 | markets.businessinsider.comSHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in GoodRx Holdings, Inc. with Losses to Contact the FirmMay 6, 2024 | businesswire.comGlancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against GoodRx Holdings, Inc. (GDRX)May 8, 2024 | Priority Gold (Ad)Biden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...May 6, 2024 | prnewswire.comLost Money on GoodRx Holdings, Inc.(GDRX)? Join Class Action Suit Seeking Recovery - Contact Levi & KorsinskyMay 5, 2024 | prnewswire.comROSEN, TOP RANKED INVESTOR COUNSEL, Encourages GoodRx Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GDRXMay 3, 2024 | prnewswire.comSHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of GoodRxMay 3, 2024 | prnewswire.comGoodRx Holdings, Inc. (GDRX) Investors: June 21, 2024 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLPMay 3, 2024 | prnewswire.comClass Action Filed Against GoodRx Holdings, Inc. (GDRX) Seeking Recovery for Investors - Contact The Gross Law FirmMay 2, 2024 | businesswire.comDeadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against GoodRx Holdings, Inc. (GDRX)May 2, 2024 | americanbankingnews.comGoodRx (GDRX) to Release Quarterly Earnings on ThursdayMay 1, 2024 | prnewswire.comSHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in GoodRx Holdings, Inc. with Losses to Contact the FirmMay 1, 2024 | prnewswire.comGDRX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that GoodRx Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!April 30, 2024 | tmcnet.comThe Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of GoodRx Holdings, Inc. (GDRX) InvestorsApril 30, 2024 | markets.businessinsider.comDEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of GoodRxApril 29, 2024 | businesswire.comGoodRx Holdings, Inc. Investor Notice: Robbins LLP Reminds Stockholders of the GDRX Securities Class ActionApril 29, 2024 | businesswire.comINVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of GoodRx Holdings, Inc. (GDRX) InvestorsApril 29, 2024 | markets.businessinsider.comINVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in GoodRx Holdings, Inc. with Losses to Contact the FirmApril 29, 2024 | businesswire.comGDRX INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that GoodRx Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitApril 28, 2024 | markets.businessinsider.comDEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of GoodRxApril 28, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against GoodRx Holdings, Inc. - GDRXApril 26, 2024 | prnewswire.comROSEN, TOP RANKED INVESTOR COUNSEL, Encourages GoodRx Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GDRXSee More Headlines Receive GDRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GoodRx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/29/2024Today5/07/2024Next Earnings (Confirmed)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Data processing & preparation Sub-IndustryN/A Current SymbolNASDAQ:GDRX CUSIPN/A CIK1809519 Webwww.goodrx.com Phone855-268-2822FaxN/AEmployees694Year FoundedN/APrice Target and Rating Average Stock Price Target$8.78 High Stock Price Target$14.00 Low Stock Price Target$4.50 Potential Upside/Downside+16.6%Consensus RatingHold Rating Score (0-4)2.47 Research Coverage19 Analysts Profitability EPS (Most Recent Fiscal Year)($0.02) Trailing P/E RatioN/A Forward P/E Ratio32.74 P/E Growth3.89Net Income$-8,870,000.00 Net Margins-1.18% Pretax Margin-7.41% Return on Equity2.45% Return on Assets1.25% Debt Debt-to-Equity Ratio0.85 Current Ratio7.12 Quick Ratio7.12 Sales & Book Value Annual Sales$750.27 million Price / Sales3.96 Cash Flow$0.44 per share Price / Cash Flow17.20 Book Value$1.93 per share Price / Book3.90Miscellaneous Outstanding Shares395,000,000Free Float389,586,000Market Cap$2.97 billion OptionableOptionable Beta1.37 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Trevor Bezdek (Age 46)Co-founder & Chairman Comp: $537kMr. Douglas Joseph Hirsch (Age 53)Co-founder, Chief Mission Officer & Director Comp: $507.29kMr. Karsten Ian Voermann (Age 54)CFO & Principal Financial Officer Comp: $693.69kMr. Romin Nabiey (Age 36)Chief Accounting Officer & Principal Accounting Officer Comp: $516kMr. Scott W. Wagner (Age 53)Interim CEO & Principal Operating Officer Mr. Mike WalshPresident & Executive VP of Prescription MarketplaceMs. Whitney NotaroVice President of Investor RelationsMs. Gracye ChengGeneral Counsel & SecretaryMr. Andrew Slutsky (Age 37)Chief Marketing Officer Comp: $864.8kMs. Vina M. Leite (Age 54)Chief People Officer More ExecutivesKey CompetitorsArrowhead PharmaceuticalsNASDAQ:ARWRSummit TherapeuticsNASDAQ:SMMTACADIA PharmaceuticalsNASDAQ:ACADOlink Holding AB (publ)NASDAQ:OLKCertaraNASDAQ:CERTView All CompetitorsInsiders & InstitutionsSusquehanna Portfolio Strategies LLCSold 24,434 shares on 5/7/2024Ownership: 0.052%Swiss National BankBought 5,800 shares on 5/7/2024Ownership: 0.039%ClariVest Asset Management LLCBought 153,625 shares on 5/7/2024Ownership: 0.039%Susquehanna Fundamental Investments LLCBought 65,676 shares on 5/7/2024Ownership: 0.017%Quantbot Technologies LPBought 53,574 shares on 5/6/2024Ownership: 0.021%View All Insider TransactionsView All Institutional Transactions GDRX Stock Analysis - Frequently Asked Questions Should I buy or sell GoodRx stock right now? 19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GoodRx in the last twelve months. There are currently 1 sell rating, 8 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" GDRX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GDRX, but not buy additional shares or sell existing shares. View GDRX analyst ratings or view top-rated stocks. What is GoodRx's stock price target for 2024? 19 Wall Street research analysts have issued 12 month price objectives for GoodRx's stock. Their GDRX share price targets range from $4.50 to $14.00. On average, they predict the company's share price to reach $8.78 in the next year. This suggests a possible upside of 16.6% from the stock's current price. View analysts price targets for GDRX or view top-rated stocks among Wall Street analysts. How have GDRX shares performed in 2024? GoodRx's stock was trading at $6.70 on January 1st, 2024. Since then, GDRX shares have increased by 12.4% and is now trading at $7.53. View the best growth stocks for 2024 here. When is GoodRx's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our GDRX earnings forecast. How can I listen to GoodRx's earnings call? GoodRx will be holding an earnings conference call on Thursday, May 9th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link. How were GoodRx's earnings last quarter? GoodRx Holdings, Inc. (NASDAQ:GDRX) posted its quarterly earnings results on Thursday, February, 29th. The company reported $0.02 EPS for the quarter, meeting analysts' consensus estimates of $0.02. The company had revenue of $196.64 million for the quarter, compared to analysts' expectations of $195.59 million. GoodRx had a negative net margin of 1.18% and a positive trailing twelve-month return on equity of 2.45%. What ETFs hold GoodRx's stock? ETFs with the largest weight of GoodRx (NASDAQ:GDRX) stock in their portfolio include WisdomTree Growth Leaders Fund (PLAT), Global X Telemedicine & Digital Health ETF (EDOC) and Fidelity Digital Health ETF (FDHT).First Trust Nasdaq Lux Digital Health Solutions ETF (EKG). What guidance has GoodRx issued on next quarter's earnings? GoodRx updated its FY 2024 earnings guidance on Thursday, February, 29th. The company provided EPS guidance of for the period. The company issued revenue guidance of $800.0 million-$800.0 million, compared to the consensus revenue estimate of $790.5 million. What other stocks do shareholders of GoodRx own? Based on aggregate information from My MarketBeat watchlists, some companies that other GoodRx investors own include Gilead Sciences (GILD), NVIDIA (NVDA), AbbVie (ABBV), Bristol-Myers Squibb (BMY), DraftKings (DKNG), GW Pharmaceuticals (GWPH), Rocket Companies (RKT), AT&T (T), Advanced Micro Devices (AMD) and Alteryx (AYX). When did GoodRx IPO? GoodRx (GDRX) raised $900 million in an initial public offering (IPO) on Wednesday, September 23rd 2020. The company issued 34,600,000 shares at $24.00-$28.00 per share. Morgan Stanley, Goldman Sachs, J.P. Morgan and Barclays acted as the underwriters for the IPO and BofA Securities, Citigroup, Credit Suisse, RBC Capital Markets, UBS Investment Bank, Cowen, Deutsche Bank Securities, Evercore ISI, Citizens Capital Markets, KKR, LionTree, Raymond James, SVB Leerink, Academy Securities, Loop Capital Markets, R. Seelaus and Ramirez were co-managers. Who are GoodRx's major shareholders? GoodRx's stock is owned by a variety of retail and institutional investors. Top institutional investors include Assenagon Asset Management S.A. (0.26%), GSA Capital Partners LLP (0.06%), Susquehanna Portfolio Strategies LLC (0.05%), Mirae Asset Global Investments Co. Ltd. (0.05%), Mckinley Capital Management LLC (0.05%) and Swiss National Bank (0.04%). Insiders that own company stock include Abdiel Capital Management, Llc, Agnes Rey-Giraud, Andrew Slutsky, Babak Azad, Bansi Nagji, Douglas Joseph Hirsch, Idea Men, Llc, Karsten Voermann, Lake Group LLC Silver, Scott Wagner and Trevor Bezdek. View institutional ownership trends. How do I buy shares of GoodRx? Shares of GDRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GDRX) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersShocking: One AI startup's revenue could surge 4,735%Manward PressThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorGold Set to EXPLODE!Gold Safe ExchangeConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsAI “wealth window” is closing June 25thParadigm Press[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsStock-Picking AI Predicts #1 Stock of 2024AltimetryElon Musk Secret Crypto Plot ExposedCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GoodRx Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.